Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
Lucia De Monte, Michele Reni, Elena Tassi, Daniela Clavenna, Ilenia Papa, Helios Recalde, Marco Braga, Valerio Di Carlo, Claudio Doglioni, Maria Pia Protti, Lucia De Monte, Michele Reni, Elena Tassi, Daniela Clavenna, Ilenia Papa, Helios Recalde, Marco Braga, Valerio Di Carlo, Claudio Doglioni, Maria Pia Protti
Abstract
Pancreatic cancer is a very aggressive disease characterized by a marked desmoplasia with a predominant Th2 (GATA-3+) over Th1 (T-bet+) lymphoid infiltrate. We found that the ratio of GATA-3+/T-bet+ tumor-infiltrating lymphoid cells is an independent predictive marker of patient survival. Patients surgically treated for stage IB/III disease with a ratio inferior to the median value had a statistically significant prolonged overall survival, implying an active role for Th2 responses in disease progression. Thymic stromal lymphopoietin (TSLP), which favors Th2 cell polarization through myeloid dendritic cell (DC) conditioning, was secreted by cancer-associated fibroblasts (CAFs) after activation with tumor-derived tumor necrosis factor α and interleukin 1β. TSLP-containing supernatants from activated CAFs induced in vitro myeloid DCs to up-regulate the TSLP receptor (TSLPR), secrete Th2-attracting chemokines, and acquire TSLP-dependent Th2-polarizing capability in vitro. In vivo, Th2 chemoattractants were expressed in the tumor and in the stroma, and TSLPR-expressing DCs were present in the tumor stroma and in tumor-draining but not in nondraining lymph nodes. Collectively, this study identifies in pancreatic cancer a cross talk between tumor cells and CAFs, resulting in a TSLP-dependent induction of Th2-type inflammation which associates with reduced patient survival. Thus, blocking TSLP production by CAFs might help to improve prognosis in pancreatic cancer.
Figures
References
- Arlt A., Vorndamm J., Müerköster S., Yu H., Schmidt W.E., Fölsch U.R., Schäfer H. 2002. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 62:910–916
- Atzeni F., Sarzi-Puttini P. 2009. Anti-cytokine antibodies for rheumatic diseases. Curr. Opin. Investig. Drugs. 10:1204–1211
- Bogiatzi S.I., Fernandez I., Bichet J.C., Marloie-Provost M.A., Volpe E., Sastre X., Soumelis V. 2007. Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J. Immunol. 178:3373–3377
- Burris H.A., III, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15:2403–2413
- Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942–949 10.1038/nm1093
- Dallal R.M., Christakos P., Lee K., Egawa S., Son Y.I., Lotze M.T. 2002. Paucity of dendritic cells in pancreatic cancer. Surgery. 131:135–138 10.1067/msy.2002.119937
- De Monte L., Sanvito F., Olivieri S., Viganò F., Doglioni C., Frasson M., Braga M., Bachi A., Dellabona P., Protti M.P., Alessio M. 2008. Serological immunoreactivity against colon cancer proteome varies upon disease progression. J. Proteome Res. 7:504–514 10.1021/pr070360m
- Dunn G.P., Old L.J., Schreiber R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329–360 10.1146/annurev.immunol.22.012703.104803
- Edwards M.J. 2008. Therapy directed against thymic stromal lymphopoietin. Drug News Perspect. 21:312–316 10.1358/dnp.2008.21.6.1246830
- Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., et al. 2008. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 68:1443–1450 10.1158/0008-5472.CAN-07-5704
- Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. 2010. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 17:135–147 10.1016/j.ccr.2009.12.041
- Evans D.B., Charnsangavei C., Fernandez-del-Castillo C., Fong Y., Lauwers G.Y. 2002. Exocrine pancreas. AJCC Cancer Staging Manual. Greene F.L., Page D.L., Fleming I.D., Fritz A.G., Balch C.M., Haller D.G., Morrow M., Springer, New York: 157–164
- Fukunaga A., Miyamoto M., Cho Y., Murakami S., Kawarada Y., Oshikiri T., Kato K., Kurokawa T., Suzuoki M., Nakakubo Y., et al. 2004. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 28:e26–e31 10.1097/00006676-200401000-00023
- Glass G., Papin J.A., Mandell J.W. 2009. SIMPLE: a sequential immunoperoxidase labeling and erasing method. J. Histochem. Cytochem. 57:899–905 10.1369/jhc.2009.953612
- Grivennikov S.I., Greten F.R., Karin M. 2010. Immunity, inflammation, and cancer. Cell. 140:883–899 10.1016/j.cell.2010.01.025
- Harrison M.L., Obermueller E., Maisey N.R., Hoare S., Edmonds K., Li N.F., Chao D., Hall K., Lee C., Timotheadou E., et al. 2007. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25:4542–4549 10.1200/JCO.2007.11.2136
- Hidalgo M. 2010. Pancreatic cancer. N. Engl. J. Med. 362:1605–1617 10.1056/NEJMra0901557
- Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4:437–450 10.1016/S1535-6108(03)00309-X
- Ito T., Wang Y.H., Duramad O., Hori T., Delespesse G.J., Watanabe N., Qin F.X., Yao Z., Cao W., Liu Y.J. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213–1223 10.1084/jem.20051135
- Joyce J.A., Pollard J.W. 2009. Microenvironmental regulation of metastasis. Nat. Rev. Cancer. 9:239–252 10.1038/nrc2618
- Kleeff J., Beckhove P., Esposito I., Herzig S., Huber P.E., Löhr J.M., Friess H. 2007. Pancreatic cancer microenvironment. Int. J. Cancer. 121:699–705 10.1002/ijc.22871
- Kurahara H., Shinchi H., Mataki Y., Maemura K., Noma H., Kubo F., Sakoda M., Ueno S., Natsugoe S., Takao S. 2009. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 10.1016/j.jss.2009.05.026
- Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P.N.; Canakinumab in CAPS Study Group 2009. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360:2416–2425 10.1056/NEJMoa0810787
- Leach S.D. 2004. Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell. 5:7–11 10.1016/S1535-6108(03)00337-4
- Lee H.C., Ziegler S.F. 2007. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc. Natl. Acad. Sci. USA. 104:914–919 10.1073/pnas.0607305104
- Liu Y.J., Soumelis V., Watanabe N., Ito T., Wang Y.H., Malefyt Rde.W., Omori M., Zhou B., Ziegler S.F. 2007. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 25:193–219 10.1146/annurev.immunol.25.022106.141718
- Lu N., Wang Y.H., Wang Y.H., Arima K., Hanabuchi S., Liu Y.J. 2009. TSLP and IL-7 use two different mechanisms to regulate human CD4+ T cell homeostasis. J. Exp. Med. 206:2111–2119 10.1084/jem.20090153
- Lust J.A., Lacy M.Q., Zeldenrust S.R., Dispenzieri A., Gertz M.A., Witzig T.E., Kumar S., Hayman S.R., Russell S.J., Buadi F.K., et al. 2009. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84:114–122 10.4065/84.2.114
- Mahadevan D., Von Hoff D.D. 2007. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 6:1186–1197 10.1158/1535-7163.MCT-06-0686
- Mantovani A., Allavena P., Sica A., Balkwill F. 2008. Cancer-related inflammation. Nature. 454:436–444 10.1038/nature07205
- Marturano J., Longhi R., Russo V., Protti M.P. 2008. Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. Cancer Res. 68:1555–1562 10.1158/0008-5472.CAN-07-5233
- Müerköster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.L., Sebens T., Klöppel G., Kalthoff H., Fölsch U.R., Schäfer H. 2004. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 64:1331–1337 10.1158/0008-5472.CAN-03-1860
- Recalde H.R. 1984. A simple method of obtaining monocytes in suspension. J. Immunol. Methods. 69:71–77 10.1016/0022-1759(84)90278-3
- Reche P.A., Soumelis V., Gorman D.M., Clifford T., Mr Liu, Travis M., Zurawski S.M., Johnston J., Liu Y.J., Spits H., et al. 2001. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J. Immunol. 167:336–343
- Reni M., Passoni P., Bonetto E., Balzano G., Panucci M.G., Zerbi A., Ronzoni M., Staudacher C., Villa E., Di Carlo V. 2005. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology. 68:239–245 10.1159/000086780
- Rimoldi M., Chieppa M., Salucci V., Avogadri F., Sonzogni A., Sampietro G.M., Nespoli A., Viale G., Allavena P., Rescigno M. 2005. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol. 6:507–514 10.1038/ni1192
- Slager E.H., Borghi M., van der Minne C.E., Aarnoudse C.A., Havenga M.J., Schrier P.I., Osanto S., Griffioen M. 2003. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J. Immunol. 170:1490–1497
- Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., Gilliet M., Ho S., Antonenko S., Lauerma A., et al. 2002. Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP. Nat. Immunol. 3:673–680 10.1038/ni805
- Tassi E., Gavazzi F., Albarello L., Senyukov V., Longhi R., Dellabona P., Doglioni C., Braga M., Di Carlo V., Protti M.P. 2008. Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 181:6595–6603
- Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok W.W., Storkus W.J. 2002. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB10401+ patients with renal cell carcinoma or melanoma. J. Exp. Med. 196:619–628 10.1084/jem.20012142
- Tatsumi T., Herrem C.J., Olson W.C., Finke J.H., Bukowski R.M., Kinch M.S., Ranieri E., Storkus W.J. 2003. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 63:4481–4489
- Tschopp J., Schroder K. 2010. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. 10:210–215 10.1038/nri2725
- van den Berg W.B. 2000. Arguments for interleukin 1 as a target in chronic arthritis. Ann. Rheum. Dis. 59:i81–i84 10.1136/ard.59.suppl_1.i81
- Wynn T.A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4:583–594 10.1038/nri1412
- Zhang K., Shan L., Rahman M.S., Unruh H., Halayko A.J., Gounni A.S. 2007. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 293:L375–L382 10.1152/ajplung.00045.2007
Source: PubMed